NOD-like receptor signaling in inflammation-associated cancers: From functions to targeted therapies
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND Recently, many studies have reported that some botanicals and natural products were able to regulate NOD-like receptor signaling. NOD-like receptors (NLRs) have been established as crucial regulators in inflammation-associated tumorigenesis, angiogenesis, cancer cell stemness and chemoresistance. NLRs specifically sense pathogen-associated molecular patterns and respond by activating other signaling regulators, including Rip2 kinase, NF-κB, MAPK and ASC/caspase-1, leading to the secretion of various cytokines. PURPOSE The aim of this article is to review the molecular mechanisms of NOD-like receptor signaling in inflammation-associated cancers and the NLRs-targeted botanicals and synthetic small molecules in cancer intervention. RESULTS Aberrant activation of NLRs occurs in various cancers, orchestrating the tissue microenvironment and potentiating neoplastic risk. Blocking NLR inflammasome activation by botanicals or synthetic small molecules may be a valuable way to prevent cancer progression. Moreover, due to the roles of NLRs in regulating cytokine production, NLR signaling may be correlated with senescence-associated secretory phenotype. CONCLUSION In this review, we discuss how NLR signaling is involved in inflammation-associated cancers, and highlight the NLR-targeted botanicals and synthetic small molecules in cancer intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T.-D., Özören, N., Jagirdar, R., Inohara, N., Vandenabeele, P., Bertin, J., Coyle, A., et al. (2006) · Nature Immunology · doi:10.1038/ni1346 · Cited by 1,131
Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf
Miao, E. A., Alpuche-Aranda, C. M., Dors, M., Clark, A. E., Bader, M. W., Miller, S. I., & Aderem, A. (2006) · Nature Immunology · doi:10.1038/ni1344 · Cited by 1,127
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Infections as a major preventable cause of human cancer
Kuper, H., Adami, H. ‐., & Trichopoulos, D. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00742.x · Cited by 740
Rossman, M. J., Santos-Parker, J. R., Steward, C. A. C., Bispham, N. Z., Cuevas, L. M., Rosenberg, H. L., Woodward, K. A., Chonchol, M., Gioscia-Ryan, R. A., Murphy, M. P., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10787 · Cited by 456
Zhong, F. L., Mamaï, O., Sborgi, L., Boussofara, L., Hopkins, R., Robinson, K., Szeverényi, I., Takeichi, T., Balaji, R., Lau, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.001 · Cited by 440
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379
Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A., Rodrigue-Gervais, I. G., Breton, V., Colpitts, S. L., Beauchemin, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.013 · Cited by 342
The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis
Chen, G. Y., Shaw, M. H., Redondo, G., & Núñez, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2061 · Cited by 261
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression
Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13007 · Cited by 239
Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells
WANG, Y., KONG, H., ZENG, X., LIU, W., WANG, Z., YAN, X., WANG, H., & XIE, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4569 · Cited by 186
The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis
Williams, T. M., Leeth, R. A., Rothschild, D. E., Coutermarsh-Ott, S. L., McDaniel, D. K., Simmons, A. E., Heid, B., Cecere, T. E., & Allen, I. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402098 · Cited by 162
Fenini, G., Grossi, S., Contassot, E., Biedermann, T., Reichmann, E., French, L. E., & Beer, H.-D. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.07.016 · Cited by 125
Sun, C., Fan, S., Wang, X., Lu, J., Zhang, Z., Wu, D., Shan, Q., & Zheng, Y. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.04.012 · Cited by 43
Cited by
Pattern recognition receptors in health and diseases
Li, D., & Wu, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00687-0 · Cited by 1,787
Metadata
- Authors
- Liu, P., Lu, Z., Liu, L., Li, R., Liang, Z., Shen, M., Xu, H., Ren, D., Ji, M., Yuan, S., Shang, D., Zhang, Y., Liu, H., & Tu, Z.
- Venue
- Phytomedicine
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 64
- Pages
- 152925
- ISSN
- 0944-7113 (ISSN-L)
- OpenAlex
- W2938048562
- Cited by
- 173
- References
- 24
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.